MYX 3.29% $4.40 mayne pharma group limited

Mithra’s Donesta phase 3 trial results

  1. 351 Posts.
    lightbulb Created with Sketch. 201
    Mithra released their stage 3 efficacy trials a couple of days ago regarding menopausal treatments.
    The results were outstanding.
    I can’t see how rulers are not being run over these companies given MYX cash position and Mithra’s
    focus on womens health.

    It’s just a matter of time IMO before we see something between these two entities.
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.